Purpose: A retrospective single-center review of ultrasound-guided radiofrequency ablation (RFA) treatment of colorectal cancer liver metastases was performed. This study reviews the primary and secondary technical effectiveness, overall survival of patients, recurrence-free survival, tumour-free survival, rates of local recurrence, and postprocedural RFA complications. Technical effectiveness and rates of complication with respect to tumour location and size were evaluated. Our results were compared with similar studies from Europe and North America. Methods: A total of 63 patients (109 tumours) treated with RFA between February 2004 and December 2009 were reviewed. Average and median follow-up time was 19.4 and 16.5 months, respectively (range, 1e54 months). Data from patient charts, pathology, and Picture Archiving and Communication System was integrated into an Excel database. Statistical Analysis Software was used for statistical analysis. Results: Primary and secondary technical effectiveness of percutaneous and intraoperative RFA were 90.8% and 92.7%, respectively. Average (SE) tumour-free survival was 14.4 AE 1.4 months (range, 1e43 months), and average (SE) recurrence-free survival was 33.5 AE 2.3 months (range, 2e50 months). Local recurrence was seen in 31.2% of treated tumours (range, 2e50 months) (34/109). Overall survival was 89.4% at 1 year, 70.0% at 2 years, and 38.1% at 3 years, with an average (SE) overall survival of 37.0 AE 2.8 months. There were 14 postprocedural complications. There was no statistically significant difference in technical effectiveness for small tumours (1e2 cm) vs intermediate ones (3e5 cm). There was no difference in technical effectiveness for peripheral vs parenchymal tumours. Conclusions: This study demonstrated good-quality outcomes for RFA treatment of colorectal cancer liver metastases from a Canadian perspective and compared favorably with published studies. R esum e Objet : Une etude r etrospective unicentrique de l'ablation par radiofr equence (ARF) de m etastases h epatiques sous contrôle echographique a et e r ealis ee chez des patients diagnostiqu es avec un cancer colorectal. Cette etude visait a analyser l'efficacit e technique primaire et secondaire, la survie globale des patients, la survie sans r ecidive, la survie sans tumeur, les taux de r ecidive locale et les complications postop eratoires a la suite d'une ARF. L'efficacit e technique et les taux de complications en fonction de l'emplacement et de la taille des tumeurs ont et e evalu es. Les r esultats furent ensuite compar es aux r esultats d' etudes similaires r ealis ees en Europe et en Am erique du Nord. M ethodes : En tout, les dossiers de 63 patients (109 tumeurs) ayant et e trait es par ARF entre f evrier 2004 et d ecembre 2009 ont et e etudi es. Les p eriodes de suivi moyenne et m ediane etaient de 19,4 et de 16,5 mois respectivement (intervalle, 1 a 54 mois). Les donn ees tir ees des dossiers des patients, des documents de pathologie et du syst eme d'archivage et de transmission d'images ont et e compil ees dans une base de donn ees Excel. L'analyse statique a ensuite r ealis e a l'aide d'un logiciel d'analyse statistique. R esultats : L'efficacit e technique primaire et secondaire des ARF r ealis ees par voie percutan ee et en salle d'op eration est de 90,8 % et de 92,7 % respectivement. La survie sans tumeur (erreur type) moyenne equivaut a 14,4 AE 1,4 mois (intervalle, 1 a 43 mois) et la survie sans r ecidive (erreur type) moyenne a 33,5 AE 2,3 mois (intervalle, 2 a 50 mois). Les r esultats d emontrent egalement que 31,2 % des tumeurs trait ees ont fait l'objet d'une r ecidive locale (intervalle, 2 a 50 mois) (34/109). Nous avons par ailleurs relev e une survie globale de 89,4 % a
un an, de 70 % a deux ans et de 38,1 % a trois ans, soit une survie globale (erreur type) moyenne de 37,0 AE 2,8 mois. Les r esultats ont aussi r ev el e 14 cas de complications postop eratoires. Enfin, aucune diff erence statistiquement significative n'a et e relev ee entre l'efficacit e technique associ ee aux tumeurs de faible taille (1 a 2 cm) et l'efficacit e technique associ ee aux tumeurs de taille moyenne (3 a 5 cm). Les tumeurs p eriph eriques et les tumeurs du parenchyme n'ont pas, non plus, pr esent e de diff erence en mati ere d'efficacit e technique. Conclusion : La pr esente etude confirme que les r esultats du traitement des m etastases h epatiques par ARF chez les patients atteints de cancer colorectal sont excellents et sont comparables aux r esultats d' etudes d ej a publi ees. Ó 2014 Canadian Association of Radiologists. All rights reserved.
Key Words: Radiofrequency ablation; Colorectal cancer metastases; Liver Colorectal cancer has an estimated incidence of 22,200 per year in Canada and is the cause of death for 8900 Canadians per year; it is also the second leading cause of cancer deaths [1] . Hepatic metastases develop in up to 50% of patients with colorectal cancer and can be categorized as resectable, potentially resectable, or unresectable [2] . Resectable tumours usually are dealt with via surgical resection and possibly with chemotherapy [3] . Unresectable tumours are increasingly being treated with a modality known as radiofrequency ablation (RFA) [4] . RFA is a thermal ablation technique that causes tissue coagulation induction by using electromagnetic energy in the range of 375-500 kHz [2, 5] . An electrical current is channeled through a metal needle electrode called the applicator; there also are dispersive electrode pads attached to the patient that act as grounding pads to complete the electrical circuit [2] . Applying this energy to a tumour causes cell death through ionic agitation and coagulation of proteins [2] . RFA can be performed intraoperatively, laparoscopically, or percutaneously with image guidance by ultrasound (US), computed tomography (CT), or magnetic resonance imaging (MRI) [2] .
A research ethics board approved a retrospective, singlecenter review of US-guided RFA treatment of colorectal cancer liver metastases (CCLM) was performed at our academic institution. This study reviewed the primary and secondary technical effectiveness, overall survival of patients, recurrence-free survival (''time from RFA until death or the longest follow-up period in which there is no evidence of recurrence of the ablated tumor'' [2] ) and tumour-free survival (time from RFA until the presence of a new hepatic or extrahepatic tumour or recurrence of the ablated tumour) as well as rates of local recurrence and postprocedural RFA complications. Technical effectiveness and rates of complication with respect to tumour location and size were evaluated. Primary technical effectiveness is defined as a tumour that was successfully eradicated after the initial intervention and/or RFA. Secondary effectiveness includes tumours that successfully underwent repeated ablation after local tumour progression [5] .
Complications are divided into major or minor categories as follows: (1) major complication, ''an event that leads to substantial morbidity and disability, increasing the level of care, or results in hospital admission or substantially lengthened hospital stay,'' or (2) minor complication, a complication that is not classified as a major complication [5] . Our results were compared with similar studies in the literature [2,6e12] . With the increasingly common usage of RFA as a treatment modality for CCLMs around the world, this study represents one of the first study from a Canadian perspective [11] .
Materials and Methods
In this study, 63 patients with 109 CCLM were treated with RFA from February 2004 to December 2009, with an average follow-up time of 19.4 months and a median followup time of 16.5 months (range, 1e54 months). Pre-RFA imaging was obtained by CT or MRI ( Figure 1A and B ). Before the procedure, the patient was evaluated by a radiologist by using US to assess technical feasibility of the procedure in terms of visualizing the lesion ( Hoffman-La Roche) (in combination with FOLFOX or FOLFIRI), and raltitrexed (Tomudex; Hospira Canada, Montreal, QC) (in combination with oxaliplatin). RFA was conducted by using probes made by either Boston Scientific (multi-tined) (Natick, MA) or Tyco/Covidien (water cooled) (Boulder, CO). The probe ablation zone sizes ranged from 2e5 cm and were chosen based on tumour size, which allowed for ablation of a margin of 0.5e1.0 cm of surrounding normal tissue. End points of an ablation when using the Boston Scientific probes is dependent on a rise in impedance as measured in the tines, whereas the Tyco/ Covidien (Boulder, CO) probes have a predetermined time during which the ablation occurs (this time is dependent on the size and type of probe used, single probe vs multiprobe). First-session RFA time varied from 4e135 minutes. Sixtynine first-session RFA treatments consisted of 51 cases that were performed percutaneously under US guidance, 17 cases that were performed intraoperatively, and 1 case that was performed under CT guidance. Sixteen repeated RFA treatments were performed; these repeated treatments were performed for either multisession ablation of a large tumour or ablation of a recurrence. An anesthetist was present for all cases after placement of the applicator, to provide conscious sedation during the procedure. Intra-RFA manipulations included 1 case of hydrodissection of bowel that was next to the liver metastasis. Dextrose 5% in water (D5W) was injected to separate the colon from the area, which reduced the risk of bowel perforation. Other manipulations included repositioning of the RFA probe to increase the size of the ablation zone in 15 cases. Post-RFA chemotherapy was administered in 39 of 63 cases. Post-RFA chemotherapy included the following regimens: 5-FU, FOLFIRI, FOLFOX, capecitabine, bevacizumab (in combination with FOLFOX, FOLFIRI, and/or 5-FU), raltitrexed, nimotuzumab (in combination with FOLFIRI), cetuximab (in combination with FOLFOX, FOLFIRI as a single agent in 1 case and in combination with irinotecan in another case), XELIRI (capecitabine and irinotecan) and panitumumab. Follow-up imaging was performed with CT or MRI for an average and median time of 19.4 and 16.5 months, respectively (range, 1e54 months) ( Figure 3) . A standard follow-up schedule included imaging at 1, 3, and 6 months, 1 year, and yearly thereafter (unless the patient's symptoms required additional cross-sectional imaging). Six patients underwent liver resection after RFA.
Data Analysis
Data from patient charts, pathology, and the Picture Archiving and Communication System (McKesson, San Francisco, CA) was integrated into an Excel database (Microsoft Corp, Redmond, WA). Primary and secondary technical effectiveness, overall survival of patients, local recurrence-free survival, tumour-free survival, and postprocedural RFA complications were determined. Technical effectiveness and rates of complication with respect to tumour location and size also were evaluated. Kaplan-Meier curves were plotted. Statistical Analysis Software (SAS Institute Inc, Cary, NC) was used for statistical analysis.
Results
Primary and secondary technical effectiveness of percutaneous and intraoperative RFA was 90.8% and 92.7%, respectively ( Table 1) . Average tumour-free survival was 14.4 AE 1.4 months (range, 1-43 month), with a median of 8.0 AE 1.1 months (Figures 4 and 5 ). Tumour-free survival is dependent on having no new lesion development anywhere in the body. Average recurrence-free survival, defined as being recurrence around the ablation zone, was 33.5 AE 2.3 months (range, 2e50 months), with a median of 32.0 AE 2.7 months ( Figure 6 ). Local recurrence was seen in 31.2% of treated tumours (34/109) (range, 2e50 months). The mean size and median size of a recurrent lesion was 2.9 cm and 2.7 cm, respectively (range, 0.8e7.1 cm). The mean and median size of a nonrecurrent lesion were 2.0 cm and 1.8 cm, respectively (range, 0.3e5.0 cm). Overall survival was 89.4% at 1 year, 70.0% at 2 years, and 38.1% at 3 years ( Figure 7 ). Average overall survival was 37.0 AE 2.8 months, with a median of 39.0 AE 4.0 months. When using nonparametric correlation coefficients (Spearman rho), there was no statistically significant difference in (1) technical effectiveness for small tumours (1e2 cm) vs intermediate ones (3e5 cm), (2) the distance of tumour to skin and technical effectiveness, or (3) lesion size and complication rate. When using the Fisher exact test, there was no difference in technical effectiveness for peripheral vs parenchymal tumours.
There were 14 postprocedural complications: 3 major and 11 minor. The major complications consisted of (1) bacteremia secondary to hepatic abscess, pneumobilia, and renal failure; (2) bilateral hydronephrosis from bladder distension or neurogenic bladder, although the exact cause is unclear; and (3) tract seeding ( Figure 8 ). The minor complications consisted of blood in the upper portion of the liver, subcapsular hematoma, perihepatic hematoma, residual cystic collection (from possible hemorrhage or bile leak), localized bleeding in xiphoid fat, subcapsular fluid with air loculi, right basilar lung atelectasis, small pneumothorax, small pleural effusion, pain, occlusion of the anterior branch of the right portal vein, and small grounding pad abrasion.
Discussion
This study is among the first, to our knowledge, to describe RFA treatment for CCLM from a Canadian perspective [11] . The goal of this study was to determine the technical and clinical success of RFA for the treatment of CCLM at our institution compared with the literature [6e12]. Various factors may affect our results, including patient access to RFA, type and duration of chemotherapy, chemotherapy administered before and/or after therapy, and regional variation in appropriate patient selection for surgery (because this may affect underlying patient medical comorbidities when the patient presents for RFA).
Typically, percutaneous RFA was not offered to patients with >3 lesions or with any lesion >5 cm in size; in these cases, intraoperative RFA for 1e3 lesions was performed in conjunction with contralateral lobar liver resection or during primary tumour resection. Pre-RFA sonographic evaluation by a radiologist was performed to confirm that the lesions were sonographically visible as well as to determine the need for additional interventions and to review the risks and benefits of RFA with the patient. It should be noted that fatty liver infiltration is common in patients who are receiving chemotherapy, and this may negatively affect ultrasound visualization of lesions. However, with cross-sectional image correlation, fewer than 10% of patients had their RFA procedure cancelled due to impaired lesion localization.
In this study, the primary technical effectiveness was 90.8%, which compared well with other studies that have technical effectiveness that range from 53.8%e96.5% (Table 1) [8e10]. The hypothesized causes of primary technical failure may be due to a number of factors, which include difficult visualization of the probe position due to patient body habitus, the presence of fatty liver infiltration, the patient's inability to hold his or her breath during probe insertion or presence of a significant heat sink (eg, the inferior vena cava (Figure 9 demonstrates a typical halo-type recurrence [13] ) was found to be 31.2% (34/109), which is similar to other studies that have rates that ranged from 8.8%-60% [7, 8, 10, 11] . Abitabile et al [8] had proposed that the low recurrence rate in their cohort may have been due to their preference for an open approach (47/70 [67.1%]) and a coagulative safety margin of at least 1 cm [8] . It also is possible that their patient population was generally healthier, with less advanced disease, given that so many patients were treated surgically. Veltri et al [10] had found that increased risk of recurrence was correlated with increased tumour size; in addition, they had a higher recurrence rate than the study by Abitabile et al [8] ; however, they only had 22 of 199 (11.1%) tumours ablated during laparotomy [10] . A study by Paulet et al [14] had shown that recurrence of ablated lesions (metastasis and hepatocellular carcinoma) was associated with the size of the lesion, patient characteristics (sex and age), and the presence of an enhanced ring seen on MRI after 6 weeks (with a postulated role of reactive hyperemia or post-RFA inflammation in recurrence) [14] . The study by Paulet et al [14] did not show any significant difference in recurrence for treatment performed percutaneously vs surgically.
In our study, 77 of 106 tumours (72.6%) were <3 cm in size, with a mean size of 2.3 cm and a median size of 2.0 cm (range, 0.3e7.1 cm). The mean and median size of a recurrent tumour was 2.9 cm and 2.7 cm, respectively (range, 0.8-7.1 cm), whereas the mean and median size of a nonrecurrent tumour was 2.0 cm and 1.8 cm, respectively (range, 0.3-5.0 cm). Thirty-one of 109 of the ablations (28.4%) were done intraoperatively. Five of 31 intraoperative treatments (16.1%) had recurrence vs 26 of 78 of percutaneous treatments (33.3%). Thus, based on our results, recurrent lesions had a larger mean and median size than nonrecurrent tumours and lower rates of recurrence were seen in intraoperative treatments. Some of the differences in outcomes are likely due to underlying comorbidities; patients with a lower tumour burden would be more likely to undergo intraoperative RFA as part of a combined procedure compared with those being treated with percutaneous RFA. Further differences in our outcomes compared with the published literature may be related to differences in Canadian chemotherapy regimens before and after RFA.
Lesion size has previously been determined to be predictive of post-RFA outcomes, including ablation success and patient survival. Siperstein et al [6] demonstrated that median survival for lesions <3 cm was 28 months and, for lesions >3 cm, was 20 months (P ¼ .07). Interestingly, when the analysis was performed by using continuous data (instead of ordinals), the median survival according to lesion size <3 cm, 3-5 cm, and >5 cm was not found to be significant [6] . Gillams and Lee [15] have also shown that the number and size of liver metastases can affect survival. Specifically, they showed that patients with 5 metastases that were 5 cm had a lower 5-year survival (34%) than those with 3 metastases that were <3.5 cm (40%) [15] . van Duijnhoven et al [9] identified that tumour size was the greatest factor, which influenced local failure rates in RFA (P < .00005). In our study, lesion size was not found to affect the rate of primary or secondary technical effectiveness, which may be due to the high rates of both primary and secondary technical effectiveness obtained overall.
Two different RFA systems with different vendors were used in this study. The Tyco/Covidien water-cooled system has a predetermined time during which the ablation occurs, depending on the size and type of probe used (single probe vs multiprobe). The Boston Scientific RF3000 is an impedance- based device that determines the end of an ablation with ''roll-off.'' The time increases with larger probes and larger lesions, and the presence of a nearby heat sink, such as a large intrahepatic vein. These various factors related to the Boston Scientific probes accounted for the wide range of ablation times.
We also sought to determine if the location of a lesion (peripheral or parenchymal) had an effect on technical effectiveness. van Duijnhoven et al [9] had previously identified that the location of the tumour was a significant factor in RFA treatment failure and reported that lesions in the central liver parenchyma (segments I, IV, and V) had a 58.7% local failure rate, whereas peripheral lesions had a local failure rate of only 38.7% (P ¼ .0052). Van Tilborg et al [12] demonstrated that the location of a tumour with respect to structures, such as large vessels, can affect the recurrence rates. In our study, there was no significant difference for peripheral vs parenchymal lesions in terms of primary technical effectiveness when using the Fisher exact test.
In addition, we wanted to determine whether the distance from the skin to the lesion could affect primary technical effectiveness. The distance of the lesion from the skin was used because this parameter may affect the RFA treatment procedure, including confidence and accuracy of probe position, and the image quality, as well as technical difficulty of the procedure. It is important to distinguish that the distance of the lesion from the skin is not necessarily reflective of body mass index but may be either due to the position of the lesion in the posterior liver or be related to patient body habitus around the area of the torso. The skinto-lesion ratio was not found to be a factor that influenced technical effectiveness.
Common chemotherapy regimens from RFA studies published in the literature were reviewed ( Table 2) . Chemotherapy agents and regimens administered both before and after RFA was similar across studies and was comparable with those used in our study. Chemotherapy administered before RFA included 5-FU, FOLFOX, or FOLFIRI and FOLFOX with or without bevacizumab [16e19]. Post-RFA chemotherapy regimens often remained the same if there was evidence of efficacy in the pretreatment setting. If no pre-RFA treatment was administered, then the patients often received up to 6 months of 5-FUebased treatment, including monotherapy and combination therapy, such as FOLFOX and FOLFIRI with or without bevacizumab [7, 16, 17, 20] . It is interesting to note that recent advances in personalized therapy have led to the increasing use of molecularly targeted agents, including monoclonal antibodies, such as bevacizumab, cetuximab, and panitumumab, in combination with traditional chemotherapy in the management of metastatic colorectal cancer [18, 21] .
A limitation of this review is the lack of clear data that state whether treatment was with curative or palliative intent; both cohorts were included in the results. The more patients treated for palliation, the higher the likelihood that there will be lower recurrence-free survival. A further limitation is the varied chemotherapy regimens for each patient, which, too, may affect patient tumour-free survival. Figure 9 . Coronal image on magnetic resonance imaging of a local recurrence. There is a halo-type recurrence as previously described by Chopra et al [13] (black arrow and arrowheads), indicating local recurrence around the previously treated colorectal cancer metastasis to the liver (white arrow). 
Conclusion
This study compares favorably with other studies on RFA treatment in CCLM [2] . High technical effectiveness and overall survival was demonstrated here. Local recurrence was seen in 31.2% of treated tumours, which compared favorably with the literature, in which recurrence rates that range from 8.8%-60% are quoted [7, 8, 10, 11] . In conclusion, this study demonstrated good primary and secondary technical effectiveness, overall survival, average tumour-free survival, and average recurrence-free survival for RFA treatment of CCLM. In addition, lesion distance from the skin surface and the size of the lesion did not affect technical effectiveness in appropriately chosen patients. This study continues to build evidence for RFA as a safe and effective treatment for hepatic oligometastases. Further investigations into the possible underlying causes and patterns of local recurrences will be undertaken to try to reduce this complication in future patients.
